Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2013
Reporting Period: Quarter ended June 30, 2013
This filing serves as a notification that the company announced its financial results for the second quarter of 2013. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the results for the quarter ended June 30, 2013.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It explicitly states that the information in this Form 8-K and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2013) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the financial results and any operational updates not included in this summary.
- Note that the financial data in this filing is not incorporated by reference into other SEC filings unless expressly stated.